Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Activates the Nrf2 pathway and may suppress pro-inflammatory NF-kB signalling. The precise mechanism by which omaveloxolone improves neurological function in Friedreich ataxia is not fully established; its action is associated with regulation of cellular antioxidant and mitochondrial stress responses.
Indications / reported uses
Treatment of Friedreich ataxia in adults and adolescents aged 16 years and older under the US SKYCLARYS indication; clinical benefit should be interpreted within the approved label and long-term monitoring requirements
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Omaveloxolone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Omaveloxolone Permitted Daily Exposure (PDE) report (the Omaveloxolone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Omaveloxolone Occupational Exposure Limit (OEL) report (the Omaveloxolone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.